K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 222 JPY -0.82% Market Closed
Market Cap: 159.9B JPY
Have any thoughts about
Kaken Pharmaceutical Co Ltd?
Write Note

Balance Sheet

Balance Sheet Decomposition
Kaken Pharmaceutical Co Ltd

Current Assets 122.7B
Cash & Short-Term Investments 84B
Receivables 21B
Other Current Assets 17.7B
Non-Current Assets 64.4B
Long-Term Investments 19.1B
PP&E 26.5B
Intangibles 7.4B
Other Non-Current Assets 11.5B
Current Liabilities 23.7B
Accounts Payable 6B
Accrued Liabilities 884m
Short-Term Debt 3.9B
Other Current Liabilities 12.9B
Non-Current Liabilities 9B
Other Non-Current Liabilities 9B

Balance Sheet
Kaken Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: JPY
Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022 Mar-2023 Mar-2024
Assets
Cash & Cash Equivalents
10 553
29 845
33 867
45 095
46 956
59 722
63 706
61 025
59 561
50 625
Cash Equivalents
10 553
29 845
33 867
45 095
46 956
59 722
63 706
61 025
59 561
50 625
Short-Term Investments
14 214
11 899
9 899
7 599
11 599
13 599
13 599
13 599
14 699
14 699
Total Receivables
28 204
29 868
28 231
33 315
30 340
21 800
20 549
20 260
19 268
23 744
Accounts Receivables
28 204
29 868
28 231
33 315
30 340
21 800
20 549
20 260
18 986
23 447
Other Receivables
0
0
0
0
0
0
0
0
282
297
Inventory
13 482
14 506
16 495
16 651
13 719
12 274
15 197
14 980
15 563
17 167
Other Current Assets
2 563
2 873
2 002
1 199
1 117
941
611
749
812
739
Total Current Assets
69 016
88 991
90 494
103 859
103 731
108 336
113 662
110 613
109 903
106 974
PP&E Net
25 961
26 726
26 271
26 141
26 402
25 518
25 020
25 734
25 498
25 355
PP&E Gross
25 961
26 726
26 271
26 141
26 402
25 518
25 020
25 734
25 498
25 355
Accumulated Depreciation
42 291
40 348
41 114
41 905
42 482
43 881
44 330
45 564
47 189
48 583
Intangible Assets
474
371
372
552
551
414
625
8 236
6 741
7 462
Long-Term Investments
15 357
14 400
15 943
18 488
17 068
15 036
17 368
17 093
17 511
20 532
Other Long-Term Assets
4 327
2 503
1 980
3 377
8 233
8 571
6 657
3 505
6 675
11 300
Total Assets
115 135
N/A
132 991
+16%
135 060
+2%
152 417
+13%
155 985
+2%
157 875
+1%
163 332
+3%
165 181
+1%
166 328
+1%
171 623
+3%
Liabilities
Accounts Payable
12 295
12 256
11 161
13 452
12 258
8 682
8 569
5 939
6 219
7 099
Accrued Liabilities
1 902
2 178
1 792
2 017
1 662
1 710
1 450
1 394
1 561
1 639
Short-Term Debt
4 195
3 875
3 875
3 875
3 875
3 850
3 850
3 850
3 850
3 850
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
Other Current Liabilities
11 977
15 552
7 192
12 057
9 785
7 413
7 407
7 866
9 208
6 436
Total Current Liabilities
30 369
33 861
24 020
31 401
27 580
21 655
21 276
19 049
20 838
19 024
Long-Term Debt
0
0
0
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
2 229
1 771
1 947
Minority Interest
0
0
0
0
0
0
0
578
578
0
Other Liabilities
7 545
9 255
8 385
7 142
7 274
7 752
5 799
5 578
6 883
6 897
Total Liabilities
38 035
N/A
43 116
+13%
32 405
-25%
38 543
+19%
34 854
-10%
29 407
-16%
27 075
-8%
27 434
+1%
30 070
+10%
27 868
-7%
Equity
Common Stock
23 853
23 853
23 853
23 853
23 853
23 853
23 853
23 853
23 853
23 853
Retained Earnings
52 932
68 609
84 331
97 284
109 057
114 869
122 462
126 347
126 135
128 506
Additional Paid In Capital
11 406
11 407
11 407
11 408
11 408
11 406
11 406
11 406
11 406
11 462
Unrealized Security Profit/Loss
5 478
0
4 611
5 510
4 524
3 116
4 739
4 551
4 724
7 184
Treasury Stock
16 098
0
19 813
23 259
26 782
23 373
26 304
28 714
30 026
28 613
Other Equity
471
2 116
1 734
922
929
1 403
101
304
166
1 363
Total Equity
77 100
N/A
89 875
+17%
102 655
+14%
113 874
+11%
121 131
+6%
128 468
+6%
136 257
+6%
137 747
+1%
136 258
-1%
143 755
+6%
Total Liabilities & Equity
115 135
N/A
132 991
+16%
135 060
+2%
152 417
+13%
155 985
+2%
157 875
+1%
163 332
+3%
165 181
+1%
166 328
+1%
171 623
+3%
Shares Outstanding
Common Shares Outstanding
41
41
41
40
40
39
38
38
37
38

See Also

Discover More